An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 18 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jul 2011 Planned end date changed from Dec 2010 to Dec 2012 as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from not yet recruiting to recruiting as reported by Roche website..